

PI Name	Protocol No.	Title	CRC
<b>ADULT TRIALS</b>			
<b>BONE MARROW CONSORTIUM</b>			
Loughran, Thomas	LOUGHRAN-2003-260	Pathogenesis of LGL Leukemia	Kendall Baab 717-531-6308 Pager 2970
Loughran, Thomas	LOUGHRAN-2003-276	Large Granular Lymphocyte (LGL) Leukemia Registry	Kendall Baab 717-531-6308 Pager 2970
<b>BRAIN</b>			
Varlotto, John	PSHCI-09-102	Phase III Trial on Concurrent and Adjuvant Temozolomide Chemotherapy in Non-1p/19q Deleted Anaplastic Glioma: The CATNON Intergroup Trial ( <b>RTOG 0834</b> )	Missy Crain 717-531-0003 ext 289630 pager 0436
Varlotto, John	PSHCI-10-026	Phase I/III Study of Image-Guided Radiosurgery/SBRT for Localized Spine Metastasis Coordinated by the Radiation Therapy Oncology Group ( <b>RTOG 0631</b> )	Missy Crain 717-531-0003 ext 289630 pager 0436
Varlotto, John	PSHCI-11-106	Natural History of Postoperative Cognitive Function, Quality of Life, and Seizure Control in Patients with Supratentorial Low-Risk Grade II Glioma ( <b>R0925</b> )	Missy Crain 717-531-0003 ext 289630 pager 0436
Glantz, Michael	PSHCI-11-012	A Randomized Phase I/II Study of ABT-888 in Combination with Temozolomide in Recurrent (Temozolomide Resistant) Glioblastoma ( <b>RTOG 0929</b> )	Carla Baynham 717-531-0003 ext 287366
Glantz, Michael	PSHCI-11-119	A Randomized, Double-blind, Controlled Phase II Study of the Safety and Efficacy of ICT-107 in Newly Diagnosed Patients with Glioblastoma Multiforme Following Resection and Chemoradiation ( <b>ImmunoCellular</b> )	Carla Baynham 717-531-0003 ext 287366
Glantz, Michael	PSHCI-12-032	PPX and Concurrent Radiation for Newly Diagnosed Glioblastoma Without MGMT Methylation: A Randomized Phase II Study ( <b>BRUOG Brown University</b> )	Carla Baynham 717-531-0003 ext 287366
Sheehan, Jonas	PSHCI-12-033	Open-label Phase 1/2 (Safety Lead-in) Study of Trans Sodium Crocetin (TSC) with Concomitant Treatment of Fractionated Radiation Therapy and Temozolomide in Newly Diagnosed Glioblastoma (GBM) Patients to Evaluate Safety and Efficacy ( <b>Diffusion Pharmaceuticals</b> )	Carla Baynham 717-531-0003 ext 287366
<b>BREAST</b>			
Smith, J Stanley	PSHCI-08-102	A Phase II Trial Exploring the Success of Cryoablation Therapy in the Treatment of Invasive Breast Carcinoma ( <b>Z1072</b> )	JoAnn Fahringer 717-531-0003 ext 285237 pager 1845
Smith, J Stanley	PSHCI-09-061	A Phase III Clinical trial comparing Trastuzumab given concurrently with Radiation Therapy and Radiation Therapy alone for Women with HER2-Positive Ductal Carcinoma in Situ Resected by Lumpectomy ( <b>B-43</b> )	JoAnn Fahringer 717-531-0003 ext 285237 pager 1845
Harvey, Harold	PSHCI-10-028	Randomized Phase II Trial of ABT-888 vs. ABT-888 in Combination with Carboplatin in Patients with Stage IV BRCA-associated Breast Cancer ( <b>NCI 8264</b> )	JoAnn Fahringer 717-531-0003 ext 285237 pager 1845
Cream, Leah	PSHCI-10-082	A Phase II Prospective Trial Correlating Progression Free Survival with CYP2D6 Activity in Patients with Metastatic Breast Cancer Treated with Single Agent Tamoxifen ( <b>E3108</b> )	JoAnn Fahringer 717-531-0003 ext 285237 pager 1845
Cream, Leah	PSHCI-10-113	A Phase III Randomized Trial of Metformin Versus Placebo on Recurrence and Survival in Early Stage Breast Cancer ( <b>MA 32</b> )	JoAnn Fahringer 717-531-0003 ext 285237 pager 1845
Smith, J Stanley	PSHCI-11-017	Phase III Randomized Study of Early Local Therapy Comprising Surgery Versus Standard Palliative Therapy for the Intact Primary Tumor in Patients With Stage IV Breast Cancer ( <b>E2108</b> )	JoAnn Fahringer 717-531-0003 ext 285237 pager 1845
Harvey, Harold	PSHCI-11-018	A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women with Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer ( <b>NSABP B-47</b> )	JoAnn Fahringer 717-531-0003 ext 285237 pager 1845
Smith, J Stanley	PSHCI-11-076	A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients with 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer with Recurrence Score (RS) of 25 or Less ( <b>S1007</b> )	Jo Ann Fahringer 717-531-0003 ext 285237 pager 1845

PI Name	Protocol No.	Title	CRC
<b>BREAST</b>			
Lipton, Allan	PSHCI-11-090	A Randomized Phase 2 Study of the Efficacy and Tolerability of Veliparib in Combination with Temozolomide or Veliparib in Combination with Carboplatin and Paclitaxel Versus Placebo Plus Carboplatin and Paclitaxel in Subjects with BRCA1 or BRCA2 Mutation and Metastatic Breast Cancer ( <b>ABBOTT LABS</b> )	Cindy Campbell Baird 717-531-5777
Truica, Cristina	PSHCI-12-043	A Phase III Clinical Trial Comparing the Combination of Docetaxel Plus Cyclophosphamide to Anthracycline-Based Chemotherapy Regimens for Women with Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer ( <b>B-49</b> )	Jo Ann Fahringer 717-531-0003 ext 285237 pager 1845
Wagner, Henry	PSHCI-12-045	A Phase III Trial of Accelerated Whole Breast Irradiation With Hypofractionation Plus Concurrent Boost Versus Standard Whole Breast Irradiation Plus Sequential Boost For Early-Stage Breast Cancer ( <b>RTOG 1005</b> )	Jo Ann Fahringer 717-531-0003 ext 285237 pager 1845
Wagner, Henry	PSHCI-12-086	A Phase II Study of Repeat Breast Preserving Surgery and 3D-Conformal Partial Breast Re-Irradiation (PBRI) For Local Recurrence of Breast Carcinoma	Jo Ann Fahringer 717-531-0003 ext 285237 pager 1845
<b>CARCINOID SYNDROME</b> (No Carcinoid Syndrome trials as of 1/14/2013)			
<b>CORRELATIVE SCIENCE/BANKING</b>			
Claxton, David	CLAXTON-2000-186	Blood and Bone Marrow Sampling for Tissue Banking	Mary Lander 717-531-7417 pager 0207
Claxton, David	PSHCI-08-065	Biologic Studies of Experimental Anti-Cancer Therapeutics in Human Leukemia Cells	Brian Barth/David Claxton 717-531-8399
Drabick, Joseph	PSHCI-10-061	General Protocol for the Acquisition of Whole Blood for the Detection and Characterization of Circulating Tumor Cells and/or Tumor Specific Immunity/Immune Cell Activation for any Malignancy at any Stage of Disease	Joseph Drabick 717-531-8677
Loughran, Thomas	PSHCI-08-070	Sphingolipid Metabolism in Acute Myelogenous Leukemia	Su-Fern Tan 717-531-0003 ext 284204
Rybka, Witold	ECOG-E3A05	Ancillary Laboratory Protocol for Collecting Diagnostic Material on Patients Considered for Studies of Plasma Cell Disorders	Mary Lander 717-531-7417 pager 0207
Rybka, Witold	RYBKA-2002-197EP	Protocol for a Research Sample Repository for Allogeneic Hematopoietic Stem Cell Transplantation	Mary Lander 717-531-7417 pager 0207
<b>CORRELATIVE SCIENCE/BANKING</b>			
Rybka, Witold	RYBKA-2002-198EP	Protocol for a Research Database for Hematopoietic Stem Cell Transplantation and Marrow Toxic Injuries	Mary Lander 717-531-7417 pager 0207
Smith, J Stanley	SMITH-2003-138	Collection of Participant Blood, Tissue, and Phenotypic Data for Inclusion in a Repository and Use in Outcome Studies	Molly Pells 717-531-5794 pager 3037
Neves, Rogerio	PSHCI-09-052	The Collection of Blood, Tissue and Phenotypic Data in Patients diagnosed with Skin Cancers and Subsequent Metastases for Inclusion in a repository and use in outcome studies	Rogerio Neves 717-531-8371
El-Deiry, Wakif	PSHCI-10-066	Prevalence of Stem Cell and Prognostic Markers in Circulating Tumor Cells of Patients With Metastatic Colorectal Cancer Undergoing Chemotherapy	David Dicker 717-531-0003 ext 289624
El-Deiry, Wakif	PSHCI-11-007	Sensitivity of Colon Cancer Tissue and Stroma to Trail and Trail-Based Therapies	Wafik El-Deiry 717-531-3609
El-Deiry, Wakif	PSHCI-11-064	Plk2-TSK Interactions and Tumor Progression in Colorectal Cancer	Wafik El-Deiry 717-531-3609
Goldenberg, David	PSHCI-10-030	Pigmentation of Papillary Thyroid Carcinoma Lymph Node Metastases	David Goldenberg 717-531-8945
Varlotto, John	PSHCI-10-094	Immune correlates of pulmonary inflammation, fibrosis and function following stereotactic body radiosurgery-induced injury	John Varlotto 717-531-8705
Kalifi, Jussuf	PSHCI-12-058	Perioperative Detection and Characterization of Circulating Tumor Cells in Patients Undergoing Colorectal Cancer Liver and Lung Metastectomy	Jussuf Kalifi 717-531-5965
Belani, Chandra	PSHCI-12-064	Oncogenic Mutations/Gene Rearrangements in Patients with Advanced Adenocarcinoma Lung	Xin Liu 717-531-3073
Belani, Chandra	PSHCI-12-017	Development of Proteomic Biomarkers for Early Lung Cancer Detection and Development	Wanda Neidig 717-531-1002 pager 3159

PI Name	Protocol No.	Title	CRC
<b>GI</b>			
Gusani, Nirai	PSHCI-10-063	Phase III Hyper Acute Pancreatic Cancer Vaccine Study	Michele St Pierre 717-531-0003 ext 287412 pager 2324
<b>GU</b>			
Juliano, Justin	PSHCI-10-077	A Phase III Prospective Randomized Trial of Dose-Escalated Radiotherapy with or without Short-Term Androgen Deprivation Therapy for Patients With Intermediate-Risk Prostate Cancer ( <b>R0815</b> )	Missy Crain 717-531-0003 ext 289630 pager 0436
Juliano, Justin	PSHCI-11-086	A Phase III Trial of Short Term Androgen Deprivation with Pelvic Lymph Node or Prostate Bed Only Radiotherapy (SPPORT) in Prostate Cancer Patients with a Rising PSA After Radical Prostatectomy ( <b>RTOG 0534</b> )	Missy Crain 717-531-0003 ext 289630 pager 0436
Juliano, Justin	PSHCI-11-087	Androgen Deprivation Therapy and High Dose Radiotherapy With or Without Whole-Pelvic Radiotherapy in Unfavorable Intermediate or Favorable High Risk Prostate Cancer: A Phase III Randomized Trial ( <b>RTOG 0924</b> )	Missy Crain 717-531-0003 ext 289630 pager 0436
Drabick, Joseph	PSHCI-10-084	Randomized Phase III Trial Comparing Everolimus Plus Placebo Versus Everolimus Plus Bevacizumab for Advanced Renal Cell Carcinoma Progressing After Treatment with Tyrosine Kinase Inhibitors ( <b>CALGB 90802</b> )	Missy Crain 717-531-0003 ext 289630 pager 0436
<b>GYN</b>			
Fanning, James	187	Phase II Study of Paclitaxel for Ovarian Stromal Tumors as Second Line Therapy	Ann Gelder 717-531-8144 pager 1488
Fanning, James	212	A Randomized Phase III Trial of Maintenance Chemotherapy Comparing 12 Monthly Cycles of Single Agent Paclitaxel or Zytax Versus No treatment Until Documented Relapse in Women with Advanced Ovarian or Primary Peritoneal Cancer who Achieve a Complete Clinical Response to Primary Platinum/Taxane Chemotherapy	Ann Gelder 717-531-8144 pager 1488
Fanning, James	PSHCI-09-063	A Phase III Trial of Pelvic Radiation Therapy versus Vaginal Cuff Brachytherapy followed by Paclitaxel, Carboplatin Chemotherapy in Patients with High Risk, Early Stage Endometrial Carcinoma ( <b>GOG 249</b> )	Ann Gelder 717-531-8144 pager 1488
Fanning, James	PSHCI-09-064	A Phase III Randomized Controlled Clinical Trial of Carboplatin and Paclitaxel Alone or in Combination with Bevacizumab Followed by Bevacizumab and Secondary Cytoreductive Surgery in Platinum Sensitive, Recurrent Ovarian, Peritoneal Primary and Fallopian Tube Cancer ( <b>GOG 213</b> )	Ann Gelder 717-531-8144 pager 1488
Fanning, James	PSHCI-09-073	A Randomized phase III trial of Cisplatin and Tumor Volume Directed Irradiation Followed by Carboplatin and Paclitaxel vs. Carboplatin and Paclitaxel for Optimally Debulked, Advanced Endometrial Carcinoma ( <b>GOG 258</b> )	Ann Gelder 717-531-8144 pager 1488
Fanning, James	PSHCI-09-079	A Randomized Phase III Trial of Paclitaxel Plus Carboplatin vs Ifosfamide plus Paclitaxel in Chemotherapy Naïve Patients with Newly Diagnosed Stage I-IV, Persistent, or Recurrent Carcinosarcoma (Mixed Mesodermal Tumors) of the Uterus ( <b>GOG 261</b> )	Ann Gelder 717-531-8144 pager 1488
Fanning, James	PSHCI-10-034	A Randomized, Phase III Evaluation of Docetaxel and Gemcitabine plus G-CSF with Bevacizumab versus Docetaxel and Gemcitabine plus G-CSF with Placebo in the Treatment of Recurrent or Advanced Leiomyosarcoma of the Uterus ( <b>GOG 250</b> )	Ann Gelder 717-531-8144 pager 1488
Fanning, James	PSHCI-10-048	Expression of Opioid Growth Factor Peptide and Opioid Growth Factor Receptor in Ovarian Tissue	Dr Fanning 717 531 8144
<b>HEAD AND NECK</b> (None as of 1/14/2013)			

PI Name	Protocol No.	Title	CRC
<b>HEMATOLOGY/OTHER (None as of 1/14/13)</b>			
<b>LEUKEMIA</b>			
Rybka, Witold	ECOG-E2903	Phase II Trial of Pentostatin, Cyclophosphamide and Rituximab (PCR) Followed by Campath-1H for Previously Treated Relapsed or Refractory patients with Chronic Lymphocytic Leukemia	Mary Lander 717-531-7417 pager 0207
Claxton, David	PSHCI-08-031	A Phase 1 Trial of the Immunostimulant JVRS-100 for the Treatment of Patients with Relapsed or Refractory Leukemia	Christine Capper 717-531-0003 ext 285453 pager 4791
Claxton, David	PSHCI-09-083	A Phase II Randomized Trial of Carboplatin and Topotecan; Flavopiridol, Mitoxantrone and Cytosine Arabinoside; and Sirolimus, Mitoxantrone, Etoposide and Cytosine Arabinoside for the Treatment of Adults with Primary Refractory or Initial Relapse of Acute Myelogenous Leukemia (AML) ( <b>E1906</b> )	Mary Lander 717-531-7417 pager 0207
Claxton, David	PSHCI-10-081	A Phase III Randoized Study of Oral Sapacitabine in Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia ( <b>Cyclacel Ltd</b> )	Christine Capper 717-531-0003 ext 285453 pager 4791
Claxton, David	PSHCI-10-088	A Phase II Randomized Trial Comparing Standard and Low Dose Rituximab: Initial Treatment of Progressive Chronic Lymphocytic Leukemia in Elderly Patients Using Alemtuzumab and Rituximab ( <b>E1908</b> )	Brian Couch 717-531-0003 ext 285861 pager 0406
Claxton, David	PSHCI-10-091	Phase II Study of Combination of Hyper-CVAD and Dasatinib with or without allogeneic stem cell transplant in Patients with Philadelphia (Ph) Chromosome Positive and/or Bcr-Abl Positive Acute Lymphoblastic Leukemia (ALL) (A BMT Study) ( <b>S0805</b> )	Mary Lander 717-531-7417 pager 0207
Claxton, David	PSHCI-11-002	Phase III Randomized Trial of Clofarabine as Induction and Post-Remission Therapy vs. Standard Daunorubicin & Cytarabine Induction and Intermediate Dose Cytarabine Post-Remission Therapy, Followed by Decitabine Maintenance vs. Observation in Newly-Diagnosed Acute Myeloid Leukemia in Older Adults (Age $\geq$ 60 years) ( <b>E2906</b> )	Mary Lander 717-531-7417 pager 0207
Rybka, Witold	PSHCI-11-040	A randomized, prospective, double blind, placebo-controlled, phase 3 study of US-ATG-F prophylaxis as a supplement to standard of care prophylaxis to prevent moderate to severe chronic GVHD in adult acute myeloid leukemia, acute lymphoid leukemia, and myelodysplastic syndrome patients after allogeneic stem cell transplantation from unrelated donors (IV-ATG-SCT-01)	Brian Couch 717-531-0003 ext 285861 pager 0406
Claxton, David	PSHCI-11-085	A Phase 2, Randomized, Open-Label Study of the Safety and Efficacy of Two Doses of Quizartinib (AC220; ASP2689) in Subjects with FLT3-ITD Positive Relapsed or Refractory Acute Myeloid Leukemia (AML) ( <b>Astellas Pharma (APGD)</b> )	Christine Capper 717-531-0003 ext 285453 pager 4791
<b>LYMPHOMA</b>			
Ehmann, W Christopher	PSHCI-09-035	A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase III study of RAD001 Adjuvant Therapy in Poor Risk Patients with Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 versus Matching Placebo after Patients have Achieved Complete Response with First-Line Rituximabchemotherapy ( <b>Novartis</b> )	Mary Lander 717-531-7417 pager 0207
Ehmann, W Christopher	PSHCI-10-093	An Open-Label, Randomized, Phase 3 Study of Inotuzumab Ozogamicin Administered in Combination with Rituximab Compared to Defined Investigator's Choice Therapy in Subjects with Relapsed or Refractory CD22-Positive Aggressive Non-Hodgkin Lymphoma Who are Not Candidates for Intensive High-Dose Chemotherapy ( <b>Pfizer, Inc</b> )	Christine Capper 717-531-0003 ext 285453 pager 4791
Epner, Elliot	PSHCI-09-018	Phase II Study of Vorinostat (SAHA), Cladribine, and Rituximab (SCR) in previously Untreated Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia, and Relapsed B-cell Non-Hodgkins Lymphoma	Christine Capper 717-531-0003 ext 285453 pager 4791
Epner, Elliot	PSHCI-10-011	Bortezomib (VELCADE), Cladribine, and Rituximab (VCR) in Mantle Cell Lymphoma	Christine Capper 717-531-0003 ext 285453 pager 4791
Epner, Elliot	PSHCI-10-105	Phase III Randomized Study of R-CHOP v. Dose-Adjusted EPOCH-R with Molecular Profiling in Untreated De Novo Diffuse Large B-Cell Lymphomas ( <b>CALGB 50303</b> )	Christine Capper 717-531-0003 ext 285453 pager 4791
Epner, Elliot	PSHCI-11-100	A 3-Arm Randomized Phase II Trial of Bendamustine-Rituximab (BR) Followed by Rituximab vs Bortezomib-BR (BVR) Followed by Rituximab vs BR Followed by Lenalidomide/Rituximab in High Risk Follicular Lymphoma ( <b>E2408</b> )	Christine Capper 717-531-0003 ext 285453 pager 4791

PI Name	Protocol No.	Title	CRC
<b>MDS (None as of 1/14/13)</b>			
<b>MELANOMA</b>			
Drabick, Joseph	PSHCI-09-030	A Phase II Trial of Dasatinib in KIT-Positive Patients with Unresectable Locally Advanced or Stage IV Mucosal, Acral and Vulvovaginal Melanomas ( <b>E2607</b> )	Missy Crain 717-531-0003 ext 289630 pager 0436
Neves, Rogerio	PSHCI-08-059	Multicenter Selective Lymphadenectomy Trial II (MSLT-II): A Phase III Multicenter Randomized Trial of Sentinel Lymphadenectomy and Complete Lymph Node Dissection Versus Sentinel Lymphadenectomy Alone in Cutaneous Melanoma Patients with Molecular or Histopathological Evidence of Metastases in the Sentinel Node. coordinated by the John Wayne Cancer Institute	Missy Crain 717-531-0003 ext 289630 pager 0436
Neves, Rogerio	PSHCI-08-080	Histological Features of Sentinel Lymph Node Biopsy for Malignant Melanoma as a Predictive Indicator for Completion Lymphadenectomy	Rogerio Neves 717-531-8371
Drabick, Joseph	PSHCI-09-067	Phase II Trial of High Dose Interleukin-2 followed by intermittent low dose Temozolomide in patients with Metastatic Malignant Melanoma	Missy Crain 717-531-0003 ext 289630 pager 0436
Drabick, Joseph	PSHCI-11-072	A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy Versus High-Dose Interferon $\alpha$ -2b for Resected High-risk Melanoma	Missy Crain 717-531-0003 ext 289630 pager 0436
<b>MYELOFIBROSIS</b>			
Claxton, David	PSHCI-11-034	An Open Label Assessment of Safety and Efficacy of Ruxolitinib (INCB018424) in Subjects with Primary Myelofibrosis, Post Essential Thrombocythemia-Myelofibrosis and Post Polycythemia Vera-Myelofibrosis who Have Platelet Counts of 50 X109/L to 100 X109/L ( <b>Incyte Corporation</b> )	Christine Capper 717-531-0003 ext 285453 pager 4791
<b>MYELOMA</b>			
Talamo, Giampaolo	PSHCI-11-015	A Trial of Single Autologous Transplant with or without Consolidation Therapy versus Tandem Autologous Transplant with Lenalidomide Maintenance for Patients with Multiple Myeloma ( <b>0702</b> )	Brian Couch 717-531-0003 ext 285861 pager 0406

PI Name	Protocol No.	Title	CRC
<b>OTHER</b>			
Rybka, Witold	ECOG-E3A05	Ancillary Laboratory Protocol for Collecting Diagnostic Material on Patients Considered for Studies of Plasma Cell Disorders	Mary Lander 717-531-7417 pager 0207
Rybka, Witold	ECOG-E3903	Ancillary Laboratory Protocol for Collecting Diagnostic Material on Patients Considered for ECOG Treatment Trials for Leukemia or Related Hematologic Disorders	Mary Lander 717-531-7417 pager 0207
Rybka, Witold	PSHCI-09-055	A Multicenter Study of Hematopoietic Stem Cell Donor Safety	Michelle Carraher 717-531-5647
Rybka, Witold	PSHCI-09-056	Ancillary HRQL Investigation	Michelle Carraher 717-531-5647
Rybka, Witold	PSHCI-10-053	A Phase III, Double-Blind, Randomized, Placebo-Controlled, Multicenter Clinical Trial to Study the Safety, Tolerability, Efficacy, and Immunogenicity of V212 in Recipients of Autologous Hematopoietic Cell Transplants (HCTs)	Brian Couch 717-531-0003 ext 285861 pager 0406
Rybka, Witold	PSHCI-11-042	A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) for Transplantation in Pediatric and Adult Patients with Hematologic Malignancies and Other Indications	Michelle Carraher 717-531-5647
<b>PHASE I</b>			
Belani, Chandra	PSHCI-09-007	A Phase I, Dose Escalation Study of the Safety, Tolerability and Pharmacokinetics of Intravenous Dimethane Sulfonate (DMS612, NSC 281612) in Advanced Malignancies (NCI 8283)	Michele St Pierre 717-531-0003 ext 287412 pager 2324
Belani, Chandra	PSHCI-10-021	Phase I Study of ABT-888 in Combination with Gemcitabine in Patients with Advanced Malignancies (NCI 8324)	Michele St Pierre 717-531-0003 ext 287412 pager 2324
Belani, Chandra	PSHCI-11-023	A Phase I Pharmacokinetic Study of Belinostat for Solid Tumors and Lymphomas in Patients with Varying Degrees of Hepatic Dysfunction (NCI 8846)	Michele St Pierre 717-531-0003 ext 287412 pager 2324
Belani, Chandra	PSHCI-11-024	Phase I Study of Veliparib (ABT-888) in Combination with Cisplatin plus Gemcitabine in Advanced Biliary, Pancreatic, Urothelial and Non-Small Cell Lung Cancer (NCI 8632)	Michele St Pierre 717-531-0003 ext 287412 pager 2324
Belani, Chandra	PSHCI-11-093	An Early Phase I Study of ABT-888 in Combination with Carboplatin and Paclitaxel in Patients with Hepatic or Renal Dysfunction and Solid Tumors (NCI 8808)	Michele St Pierre 717-531-0003 ext 287412 pager 2324
Kirschbaum, Mark	PSHCI-12-073	A Phase I Study of Ipilimumab in Combination with Rituximab in Patients with Relapsed/Refractory CD20+ B-Cell Lymphoma (9197)	Mary Lander 717-531-7417 pager 0207
Belani, Chandra	PSHCI-12-097	Phase I and Randomized Phase II Double Blind Clinical Trial of Cisplatin and Etoposide in Combination with Veliparib (ABT-888) or Placebo as Frontline Therapy for Extensive Stage Small Cell Lung Cancer (E2511)	

PI Name	Protocol No.	Title	CRC
<b>PREVENTION</b>			
Kaag, Matthew	Kaag-2007-SRC-049	Selenium and Cancer Prevention Trial	Wanda Neidig 717-531-1002 pager 3159
Foulds, Jonathan	PSHCI-11-052	The Get Quit Stay Quit Study: a randomized trial of health risk feedback and relapse prevention for treatment-seeking smokers. (Smoking Cessation)	Jonathan Foulds 717-531-3504
<b>SARCOMA</b>			
Sharma, Kamal	PSHCI-11-053	A Randomized Controlled Study of YONDELIS® (Trabectedin) or Dacarbazine for the Treatment of Advanced Liposarcoma or Leiomyosarcoma Previously Treated with an Anthracycline and Ifosfamide ( <b>Johnson &amp; Johnson</b> )	Missy Crain 717-531-0003 ext 289630 pager 0436
<b>SKIN (None as of 1/14/13)</b>			
<b>SYMPTOM MANAGEMENT/SUPPORTIVE CARE (None as of 1/14/13)</b>			
<b>THORACIC</b>			
Almokadem, Salah	ECOG-E1505	A Phase III Randomized Trial of Adjuvant Chemotherapy with or without Bevacizumab for Patients with completely Resected Stage IB (>= 4 cm) - IIIA Non-Small Cell Lung Cancer (NSCLC)	Rebecca Miller 717-531-1003 pager 3656
Belani, Chandra	PSHCI-08-082	A Phase II study of Oral Sapacitabine in Patients with Previously Treated Non-Small Cell Lung Cancer ( <b>Cyclacel</b> )	Rebecca Miller 717-531-1003 pager 3656
<b>THORACIC</b>			
Varlotto, John	PSHCI-09-078	Phase III Comparison of Thoracic Radiotherapy Regimens in patients with Limited Small Cell Lung Cancer Receiving Cisplatin and Etoposide ( <b>RTOG 0538</b> ) ( <b>CALGB 30610</b> )	Rebecca Miller 717-531-1003 pager 3656
Wagner, Henry	PSHCI-09-098	Seamless Phase I/II Study of Stereotactic Lung Radiotherapy (SBRT) for Early Stage Centrally Located, Non-Small Cell Lung Cancer (NSCLC) in Medically Inoperable Patients ( <b>RTOG 0813</b> )	Rebecca Miller 717-531-1003 pager 3656
Wagner, Henry	PSHCI-10-092	A Phase II Study of L-BLP25 and Bevacizumab in Unresectable Stage IIIA and IIIB Non-Squamous Non-Small Cell Lung Cancer after Definitive Chemoradiation ( <b>E6508</b> )	Rebecca Miller 717-531-1003 pager 3656
Belani, Chandra	PSHCI-10-043	Phase II Randomized Study of Vorinostat or Placebo in Combination with Carboplatin and Paclitaxel for Patients with Advanced Non-Small Cell Lung Cancer ( <b>8703</b> )	Rebecca Miller 717-531-1003 pager 3656
Belani, Chandra	PSHCI-10-096	Randomized Phase III Study of Maintenance Therapy with Bevacizumab, Pemetrexed, or a Combination of Bevacizumab and Pemetrexed Following Carboplatin, Paclitaxel and Bevacizumab for Advanced Non-Squamous NSCLC ( <b>E5508</b> )	Rebecca Miller 717-531-1003 pager 3656

PI Name	Protocol No.	Title	CRC
<b>PEDIATRIC TRIALS</b>			
<b>BRAIN</b>			
McGregor, Lisa	COG-ACNS0331	A Study Evaluating Limited Target Volume Boost Irradiation and Reduced Dose Craniospinal Radiotherapy 18.00 Gy and Chemotherapy In Children with Newly Diagnosed Standard Risk Medulloblastoma: A Phase III Double Randomized Trial	COG Contact 717-531-6012
McGregor, Lisa	COG-ACNS0332	Efficacy of Carboplatin Administered Concomitantly with Radiation and Isotretinoin as a Pro-Apoptotic Agent in Other than Average Risk Medulloblastoma/PNET patients	COG Contact 717-531-6012
McGregor, Lisa	COG-ACNS0333	Treatment of Atypical Teratoid/Rhabdoid Tumors (AT/RT) of the Central Nervous System with Surgery, Intensive Chemotherapy, and 3-D Conformal Radiation	COG Contact 717-531-6012
McGregor, Lisa	COG-ACNS0822	Randomized Phase II/III Study of Vorinostat and Local Irradiation or Temozolomide and Local Irradiation or Bevacizumab and Local Irradiation Followed by Maintenance Bevacizumab and Temozolomide in Children with Newly Diagnosed High-Grade Gliomas	COG Contact 717-531-6012
McGregor, Lisa	COG-ACNS0831	Phase III Randomized Trial of Post-Radiation Chemotherapy in Patients with Newly Diagnosed Ependymoma Ages 1-21 years	COG Contact 717-531-6012
McGregor, Lisa	PSHCI-10-035	A Phase I Trial Combining Decitabine and Vaccine Therapy for Patients with Relapsed Neuroblastoma and Sarcoma	Lisa McGregor 717-531-4780
McGregor, Lisa	PSHCI-11-080	Temozolomide with Irinotecan versus Temozolomide, Irinotecan plus Bevacizumab (NSC# 704865, BB-IND# 7921) for Recurrent/Refractory Medulloblastoma/CNS PNET of Childhood, A COG Randomized Phase II Screening Trial: A Groupwide Phase II Study COG <b>ACNS0821</b>	COG Contact 717-531-6012
McGregor, Lisa	PSHCI-12-040	<b>COG - ACNS1021</b> A Phase II Study of Sunitinib (NSC# 736511, IND# 74019) in Recurrent, Refractory or Progressive High Grade Glioma and Ependymoma Tumors in Pediatric and Young Adult Patients	COG Contact 717-531-6012
<b>CORRELATIVE SCIENCE/BANKING</b>			
McGregor, Lisa	COG-ABTR01B1	A Children's Oncology Group Protocol for Collecting and Banking Pediatric Research Specimens including Rare Pediatric Tumors.	COG Contact 717-531-6012
McGregor, Lisa	COG-ACCRN07	Protocol for the Enrollment on the Official COG Registry, the Childhood Cancer Research Network (CCRN)	COG Contact 717-531-6012
McGregor, Lisa	COG-ACNS02B3	A COG Protocol for Collecting and Banking Pediatric Brain Tumor Research Specimens	COG Contact 717-531-6012
McGregor, Lisa	COG-AEWS07B1	A Children's Oncology Group Protocol for Collecting and Banking Ewing Sarcoma Specimens	COG Contact 717-531-6012
McGregor, Lisa	COG-AHOD04B1	Hodgkin Disease Banking Study	COG Contact 717-531-6012
McGregor, Lisa	COG-ANHL04B1	Rare and Cutaneous Non-Hodgkin Lymphoma Registry	COG Contact 717-531-6012
McGregor, Lisa	COG-AOST06B1	A COG Protocol for Collecting and Banking Osteosarcoma Specimens	COG Contact 717-531-6012
McGregor, Lisa	COG-AREN03B2	Renal Tumor Classification, Biology, and Banking Study	COG Contact 717-531-6012
McGregor, Lisa	COG-D9902	A COG Soft Tissue Sarcoma Biology and Banking Protocol	COG Contact 717-531-6012



PI Name	Protocol No.	Title	CRC
<b>GI</b>			
McGregor, Lisa	COG-AHEP0731	Treatment of Children with All Stages of Hepatoblastoma	COG Contact 717-531-6012
Greiner, Robert	PSHCI-09-033	Defibrotide for Patients with Hepatic Venous Occlusive Disease (VOD): A Treatment IND Study (Gentium)	Kathryn Byrnes 717-531-3098
<b>GU</b>			
McGregor, Lisa	COG-AREN0532	Treatment for Very Low, Low and Standard Risk Favorable Histology Wilm's Tumor	COG Contact 717-531-6012
McGregor, Lisa	COG-AREN0533	Treatment of Newly Diagnosed Higher Risk Favorable Histology Wilms Tumor	COG Contact 717-531-6012
McGregor, Lisa	COG-AREN0534	Treatment for Patients with Bilateral, Multicentric, or Bilaterally-Predisposed Unilateral Wilms Tumor	COG Contact 717-531-6012
<b>HEAD AND NECK</b>			
McGregor, Lisa	COG-ARET0321	A Trial of Intensive Multi-Modality Therapy for Extra-Ocular Retinoblastoma	COG Contact 717-531-6012
<b>LEUKEMIA</b>			
McGregor, Lisa	COG-AALL0433	Intensive Treatment for Intermediate Risk Relapse of Childhood B-Precursor Acute Lymphoblastic Leukemia: A randomized trial of Vincristine Strategies	COG Contact 717-531-6012
McGregor, Lisa	COG-AALL0434	Intensified Methotrexate, Nelarabine and Augmented BFM therapy for Children & Young Adults with Newly Diagnosed T-cell ALL	COG Contact 717-531-6012
McGregor, Lisa	COG-AALL05B1	A Children's Oncology Group Protocol for Collecting and Banking Relapsed Acute Lymphoblastic Leukemia Research Specimens	COG Contact 717-531-6012
McGregor, Lisa	COG-AALL0631	A Phase III Study of Risk Directed Therapy for Infants with ALL: randomization of Highest Risk Infants to Intensive Chemotherapy +/- FLT3 Inhibition (CEP-701, Lestaurtinib; IND# 76431; NSC# 617807)	COG Contact 717-531-6012

PI Name	Protocol No.	Title	CRC
<b>LEUKEMIA</b>			
McGregor, Lisa	COG-AALL07P1	Phase II Pilot Trial of Bortezomib (PS-341, Velcade, IND# 58443) in Combination with Intensive Re-induction therapy for children with relapsed ALL and Lymphoblastic Lymphoma	COG Contact 717-531-6012
McGregor, Lisa	COG-AALL08B1	Classification of Newly Diagnosed Acute Lymphoblastic Leukemia	COG Contact 717-531-6012
McGregor, Lisa	COG-AALL0932	Treatment of Patients with Newly Diagnosed Standard Risk B-Precursor Acute Lymphoblastic Leukemia	COG Contact 717-531-6012
McGregor, Lisa	COG-AAML05P1	Killer Immunoglobulin-like Receptor (KIR) Incompatible Hematopoietic Cell Transplantation (HCT) for Refractory and Relapsed Acute Myelogenous Leukemia (AML) and newly diagnosed AML with monosomy 7 or -5/5q- in Children	COG Contact 717-531-6012
McGregor, Lisa	PSHCI-11-021	A Phase II Study of MLN8237 (IND# 102984), a Selective Aurora A Kinase Inhibitor in Children with Recurrent/Refractory Solid Tumors and Leukemias ( <b>ADVL0921</b> )	COG Contact 717-531-6012
Greiner, Robert	PSHCI-11-115	The Role of Minimal Residual Disease Testing before and after Hematopoietic Cell Transplantation for Pediatric Acute Myeloid Leukemia ( <b>CIBMTR 09-MRD/IRB # 28709</b> )	Jenn Stokes 717-531-7765
McGregor, Lisa	PSHCI-11-097	A Phase III Randomized Trial for Patients with de novo AML using Bortezomib (IND# 58443, NSC# 681239) and Sorafenib (BAY 43-9006, IND#68986, NSC# 724772) for Patients with High Allelic Ratio FLT3/ITD ( <b>AAML1031</b> )	COG Contact 717-531-6012
McGregor, Lisa	PSHCI-12-012	A Phase III Randomized Trial for Newly Diagnosed High Risk B-precursor Acute Lymphoblastic Leukemia (ALL) Testing Clofarabine (IND# 73789, NSC# 606869) in the Very High Risk Stratum ( <b>AALL1131</b> )	COG Contact 717-531-6012
<b>(None as of 1/14/2013)</b>			
<b>LYMPHOMA</b>			
<b>MDS</b>			
McGregor, Lisa	COG-AAML08B1	Biology Study of Transient Myeloproliferative Disorder (TMD) in Children with Down Syndrome (DS)	COG Contact 717-531-6012
<b>NEUROBLASTOMA</b>			
McGregor, Lisa	COG-ANBL0032	A Phase III Randomized Study of Chimeric Antibody 14.18 (CH14.18) in High Risk Neuroblastoma Following Myeloablative Therapy and Autologous Stem Cell Rescue	COG Contact 717-531-6012
McGregor, Lisa	COG-ANBL00B1	Neuroblastoma Biology Studies	COG Contact 717-531-6012
<b>SARCOMA</b>			
McGregor, Lisa	COG-AEWS0331	European Ewing Tumor Working Initiative of National Groups, Ewing Tumor Studies 1999 (Euro-E.W.I.N.G. 99)	COG Contact 717-531-6012
McGregor, Lisa	PSHCI-11-036	A Phase III Randomized Trial of Adding Vincristine-topotecan-cyclophosphamide to Standard Chemotherapy in Initial Treatment of Non-Metastatic Ewing Sarcoma ( <b>AEWS1031</b> )	COG Contact 717-531-6012
McGregor, Lisa	PSHCI-11-081	A Pilot Study to Evaluate Novel Agents (Temozolomide and Cixutumumab [IMC-A12, Anti-IGF-IR Monoclonal Antibody, IND #100947, NSC #742460]) in Combination With Intensive Multi-Agent Interval Compressed Therapy for Patients With High-Risk Rhabdomyosarcoma ( <b>ARST08P1</b> )	COG Contact 717-531-6012
McGregor, Lisa	PSHCI-12-031	A Randomized Phase II Trial of Bevacizumab (IND# 7921, Avastin) and Temozolomide (IND# 61010, Temisol) in Combination with Intravenous Vinorelbine and Cyclophosphamide in Patients with Recurrent/Refractory Rhabdomyosarcoma ( <b>ARST0921</b> )	COG Contact 717-531-6012
<b>SYMPTOM MANAGEMENT/SUPPORTIVE CARE</b>			
McGregor, Lisa	COG-ALTE05N1	Umbrella Long-term Follow-up Protocol	COG Contact 717-531-6012
McGregor, Lisa	COG-ALTE07C1	Neuropsychological, Social, Emotional, and Behavioral Outcomes in Children with Cancer	COG Contact 717-531-6012
Freiberg, Andrew	PSHCI-12-065	An open-label, cross-over, pharmacokinetic study to assess the safety and pharmacokinetics of transdermal granisetron (Sancuso® patch) and IV granisetron in a pediatric oncology population (ages 13-17)	Julie Vallati 717 531 3049